Replies to post #100928 on Biotech Values

[DFRAI]

MNTA lovenox costs of 143 million

would imply that MNTA expects to pay it back over 3 quarters and possibly net close to 180 million annualized revenue.

Should this happen - they would derive 3 to 3.50 in earnings x 10 pe = 35 share price for lovenox.

[DewDiligence]

In my model I estimated that MNTA development and legal cost share at ~$143M. It is not a guess but it is not rigorous either.

Rigorous or otherwise, please show your work! T.i.a.